Keywords
Key points
- •All invasive procedures involve contact by a medical device or surgical instrument with patients’ sterile tissue or mucous membrane.
- •The level of disinfection or sterilization depends on the intended use of the object: critical (items that contact sterile tissue, such as surgical instrument), semicritical (items that contact mucous membranes, such as endoscopes), and noncritical (items that contact only intact skin, such as stethoscopes) require sterilization, high-level disinfection, or low-level disinfection, respectively.
- •Cleaning must precede high-level disinfection and sterilization.
- •Failure to properly disinfect devices used in health care (eg, endoscopes) has led to many outbreaks.
- •Health care providers should be familiar with current issues, such as the role of the environment in disease transmission, reprocessing semicritical items (eg, endoscopes), and new technologies (eg, hydrogen peroxide mist).
Introduction
Centers for Disease Control and Prevention. Immediate need for healthcare facilities to review procedures for cleaning, disinfecting, and sterilizing reusable medical devices. 2015. Available at: http://emergency.cdc.gov/han/han00382.asp. Accessed 18 May, 2016.
A rational approach to disinfection and sterilization
Process | Level of Microbial Inactivation | Method | Examples (with Processing Times) | Health Care Application (Examples) |
---|---|---|---|---|
Sterilization | Destroys all microorganisms, including bacterial spores | High temperature | Steam (∼40 min), dry heat (1–6 h depending on temperature) | Heat-tolerant critical (surgical instruments) and semicritical patient-care items |
Low temperature | Ethylene oxide gas (∼15 h), HP gas plasma (28–52 min), HP and ozone (46 min), HP vapor (55 min) | Heat-sensitive critical and semicritical patient-care items | ||
Liquid immersion | Chemical sterilants b : >2% glut (∼10 h); 1.12% glut with 1.93% phenol (12 h); 7.35% HP with 0.23% PA (3 h); 8.3% HP with 7.0% PA (5 h); 7.5% HP (6 h); 1.0% HP with 0.08% PA (8 h); ≥0.2% PA (12 min at 50°C–56°C)Consult the FDA-cleared package insert for information about the cleared contact time and temperature, and see reference18 for discussion why greater than 2% glutaraldehyde products are used at a reduced exposure time (2% glutaraldehyde at 20 minutes, 20°C). Increasing the temperature using an automated endoscope reprocesser (AER) will reduce the contact time (eg, ortho-phthalaldehyde 12 minutes at 20°C but 5 minutes at 25°C in AER). Exposure temperatures for some of the aforementioned high-level disinfectants varies from 20°C to 25°C; check FDA-cleared temperature conditions.19 Tubing must be completely filled for high-level disinfection and liquid chemical sterilization. Material compatibility should be investigated when appropriate (eg, hydrogen peroxide [HP] and HP with peracetic acid will cause functional damage to endoscopes). Intermediate-level disinfectants destroy vegetative bacteria, mycobacteria, most viruses, and most fungi but not spores and may include chlorine-based products, phenolics, and improved HP. Intermediate-level disinfectants are not included in Table 1 as there as there is no device or surface for which intermediate-level disinfection is specifically recommended over low-level disinfection. | Heat-sensitive critical and semicritical patient-care items that can be immersed | ||
HLD | Destroys all microorganisms except some bacterial spores | Heat automated | Pasteurization (65°C–77°C, 30 min) | Heat-sensitive semicritical items (eg, respiratory therapy equipment) |
Liquid immersion | Chemical sterilants/HLDs b : >2% glut (20–90 min at 20°C–25°C); >2% glut (5 min at 35.0°C–37.8°C); 0.55% OPA (12 min at 20°C); 1.12% glut with 1.93% phenol (20 min at 25°C); 7.35% HP with 0.23% PA (15 min at 20°C); 7.5% HP (30 min at 20°C); 1.0% HP with 0.08% PA (25 min); 400–450 ppm chlorine (10 min at 20°C); 2.0% HP (8 min at 20°C); 3.4% glut with 26% isopropanol (10 min at 20°C)Consult the FDA-cleared package insert for information about the cleared contact time and temperature, and see reference18 for discussion why greater than 2% glutaraldehyde products are used at a reduced exposure time (2% glutaraldehyde at 20 minutes, 20°C). Increasing the temperature using an automated endoscope reprocesser (AER) will reduce the contact time (eg, ortho-phthalaldehyde 12 minutes at 20°C but 5 minutes at 25°C in AER). Exposure temperatures for some of the aforementioned high-level disinfectants varies from 20°C to 25°C; check FDA-cleared temperature conditions.19 Tubing must be completely filled for high-level disinfection and liquid chemical sterilization. Material compatibility should be investigated when appropriate (eg, hydrogen peroxide [HP] and HP with peracetic acid will cause functional damage to endoscopes). Intermediate-level disinfectants destroy vegetative bacteria, mycobacteria, most viruses, and most fungi but not spores and may include chlorine-based products, phenolics, and improved HP. Intermediate-level disinfectants are not included in Table 1 as there as there is no device or surface for which intermediate-level disinfection is specifically recommended over low-level disinfection. | Heat-sensitive semicritical items (eg, GI endoscopes, bronchoscopes, endocavitary probes) | ||
Low-level disinfection | Destroys vegetative bacteria and some fungi and viruses but not mycobacteria or spores | Liquid contact | EPA-registered hospital disinfectant with no tuberculocidal claim (eg, chlorine-based products, phenolics, improved HP, HP plus PA, quaternary ammonium compounds, exposure times at least 1 min) or 70%–90% alcohol | Noncritical patient care item (blood pressure cuff) or surface (bedside table) with no visible blood |
Food and Drug Administration. FDA-cleared sterilants and high level disinfectants with general claims for processing reusable medical and dental devices, March 2015. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm. Accessed 19 May, 2016.
Critical Items
Food and Drug Administration. FDA-cleared sterilants and high level disinfectants with general claims for processing reusable medical and dental devices, March 2015. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm. Accessed 19 May, 2016.
Sterilization Method | Advantages | Disadvantages |
---|---|---|
Peracetic acid/HP |
|
|
Glutaraldehyde |
|
|
HP |
|
|
OPA |
|
|
Peracetic acid |
|
|
Improved HP (2.0%); HLD |
|
|
Sterilization Method | Advantages | Disadvantages |
---|---|---|
Steam |
|
|
HP gas plasma |
|
|
100% ETO |
|
|
Vaporized HP |
|
|
HP and ozone |
|
|
Semicritical Items
Food and Drug Administration. FDA-cleared sterilants and high level disinfectants with general claims for processing reusable medical and dental devices, March 2015. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm. Accessed 19 May, 2016.
Food and Drug Administration. FDA-cleared sterilants and high level disinfectants with general claims for processing reusable medical and dental devices, March 2015. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm. Accessed 19 May, 2016.
Noncritical Items
Disinfectant Active | Advantages | Disadvantages |
---|---|---|
Alcohol |
|
|
Sodium hypochlorite |
|
|
Improved HP |
|
|
Iodophors |
|
|
Phenolics |
|
|
Quaternary ammonium compounds (eg, didecyl dimethyl ammonium bromide, dioctyl dimethyl ammonium bromide) |
|
|
Peracetic acid/HP |
|
|
Current issues in disinfection and sterilization
Reprocessing of Endoscopes
Outbreaks of carbapenem-resistant Enterobacteriaceae infection associated with duodenoscopes: what can we do to prevent infections?
Food and Drug Administration. Brief summary of the gastroeneterology and urology devices panel meeting, May 14-15, 2015. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ucm445590.htm. Accessed 18 May, 2016.
Food and Drug Administration. Brief summary of the gastroeneterology and urology devices panel meeting, May 14-15, 2015. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ucm445590.htm. Accessed 18 May, 2016.
Role of the Environment in Disease Transmission
Improving room cleaning and disinfection and demonstrating the effectiveness of surface decontamination in reducing health care–associated infections
Leas BF, SN, Han JH, et al. Environmental cleaning for the prevention of healthcare-associated infection. Technical brief No. 22 (prepared by the ECRI Institute – Penn Agency for Healthcare Research and Quality. Available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1951. Accessed 18 May, 2016.
No-touch (or mechanical) methods for room decontamination
Ultraviolet light for room decontamination
Hydrogen peroxide systems for room decontamination
Comparison of ultraviolet irradiation versus hydrogen peroxide for room decontamination
Author, Year | Design | Setting | Modality Tested | Pathogens | Outcome (HAI) | Assessment of HH Compliance | Assessment of EVS Cleaning | Other HAI Prevention Initiatives |
---|---|---|---|---|---|---|---|---|
Boyce, 2008 | Before-after (CDI high incidence wards) | Community hospital | HPV (Bioquell) | CDI | 2.28–1.28 per 1000 Pt-days (P = .047) | No | No | NA |
Cooper, 2011 | Before-after (2 cycles) | Hospitals | HPV (NS) | CDI | Decreased cases (incidence NS) | No | No | Yes |
Levin, 2013 | Before-after | Community hospital | UV-PX, Xenex | CDI | 9.46–4.45 per 10,000 Pt-days (P = .01) | No | No | Yes |
Passaretti, 2013 | Prospective cohort (comparison of MDRO acquisition; admitted to rooms with or without HPV decontamination) | Academic center | HPV (Bioquell) | MRSA VRE CDI MDRO-all | 2.3–1.2 (P = .30) 7.2–2.4 (P<.01) 2.4–1.0 (P=.19) 12.6–6.2 per 1000 Pt-days (P<.01) | No | No | No |
Manian, 2013 | Before-after | Community hospital | HPV (Bioquell) | CDI | 0.88–0.55 cases per 1000 Pt-days (P<.0001) | Yes | No | No |
Hass, 2014 | Before-after | Academic center | UV-PX, Xenex | CDI MRSA VRE MDRO-GNB Total | 0.79–0.65 per 1000 Pt-days (P = .02) 0.45–0.33 per 1000 Pt-days (P=.007) 0.90–0.73 per 1000 Pt-days (P = .002) 0.52–0.42 per 1000 Pt-days (P = .04) 2.67–2.14 per 1000 Pt-days (P<.001) | No | Yes | Yes |
Mitchell, 2014 | Before-after | Acute care hospital | Dry hydrogen peroxide vapor (Nocospray, New Work City, NY) | MRSA (colonization and infection) | 9.0–5.3 per 10,000 Pt-days (P<.001) | Yes | No | Yes |
Miller, 2015 | Before-after | Urban hospital | UV-PX, Xenex | CDI | 23.3–8.3 per 10,000 Pt-days (P = .02) | No | No | Yes |
Nagaraja, 2015 | Before-after | Academic center | UV-PX, Xenex | CDI | 1.06–0.83 per 1000 Pt-days (P = .06) | No | No | No |
Pegues, 2015 | Before-after | Academic center | UV-C (Optimum) | CDI | 30.34–22.85 per 10,000 Pt-days (IRR = 0.49, 95% CI 0.26–0.94, P = .03) | Yes | Yes | No |
Anderson, 2015 | RCT | 9 Hospitals | UV-C (Tru-D) | MRSA, VRE, CDI | 51.3–33.9 per 10,000 Pt-days (P = .036) | Yes | Yes | No |
- Advantages
- •There is reliable biocidal activity against a wide range of health care–associated pathogens.
- •Room surfaces and equipment are decontaminated.
- •There is rapid room decontamination (∼5–25 minutes) for vegetative bacteria, which reduces the downtime of the room before another patient can be admitted.
- •It is demonstrated to reduce HAIs (eg, C difficile, MRSA).
- •It is effective against C difficile, although requires longer exposure (∼10–50 minutes).
- •HVAC system does not need to be disabled and the room does not need to be sealed.
- •UV is residual free and does not give rise to health or safety concerns.
- •There are no consumable products, so costs include only capital equipment and staff time.
- •There is good distribution in the room of UV energy via an automated monitoring system.
- •
- Disadvantages
- •All patients and staff must be removed from the room before decontamination, thus, limiting use to terminal room decontamination.
- •Decontamination can only be accomplished at terminal disinfection (ie, cannot be used for daily disinfection) as room must be emptied of people.
- •Capital equipment costs are substantial.
- •It does not remove dust and stains, which are important to patients and visitors; hence, cleaning must precede UV decontamination.
- •It is sensitive to use parameters (eg, dose, distance, carrier or surface tested, exposure time, pathogen).
- •It requires that equipment and furniture be moved away from the walls.
- •
Ultraviolet irradiation
- Advantages
- •It has reliable biocidal activity against a wide range of health care–associated pathogens.
- •Room surfaces and equipment are decontaminated.
- •It has been demonstrated to reduce HAIs (eg, C difficile, MRSA, VRE).
- •It is useful for disinfecting complex equipment and furniture.
- •It does not require that furniture and equipment be moved away from the walls.
- •HP is residual free and does not give rise to health or safety concerns (aeration unit converts HP into oxygen and water).
- •There is uniform distribution in the room via an automated dispersal system.
- •
- Disadvantages
- •All patients and staff must be removed from the room before decontamination, thus, limiting use to terminal room decontamination.
- •HVAC system must be disabled to prevent unwanted dilution of HP during use, and the doors must be closed with gaps sealed by tape.
- •Decontamination can only be accomplished as terminal disinfection (ie, cannot be used for daily disinfection) as room must be emptied of people.
- •Capital equipment costs are substantial.
- •Decontamination requires approximately 2.0 to 5.0 hours.
- •It does not remove dust and stains, which are important to patients and visitors; hence, cleaning must precede UV decontamination.
- •It is sensitive to use parameters (eg, HP concentration, pathogen, exposure time).
- •
HP systems
Assessing Risk to Patients from Disinfection and Sterilization Failures
- 1.Confirm disinfection or sterilization reprocessing failure
- 2.Embargo any improperly disinfected or sterilized items
- 3.Do not use the questionable disinfection or sterilization unit (eg, sterilizer, automated endoscope reprocessor)
- 4.Inform key stakeholders
- 5.Conduct a complete and thorough evaluation of the cause of the disinfection/sterilization failure
- 6.Prepare a line listing of potentially exposed patients
- 7.Assess whether disinfection or sterilization failure increases patient risk for infection
- 8.Inform expanded list of stakeholders of the reprocessing issue
- 9.Develop a hypothesis for the disinfection or sterilization failure and initiate corrective action
- 10.Develop a method to assess potential adverse patient events
- 11.Consider notification of state and federal authorities
- 12.Consider patient notification
- 13.Develop long-term follow-up plan
- 14.Perform after-action report
Human Papilloma Virus
Hydrogen Peroxide Mist System for Probes
Do Not Reuse Single-Use Devices
Storage of Semicritical Items
Immersion Versus Perfusion of Channel Scopes Such as Cystoscopes
Anonymous. McGrath MAC video laryngoscope operator's manual. Available at: https://www.physio-control.com/uploadedFiles/Physio85/Contents/Emergency_Medical_Care/Products/PreHospital/MAC%20EMS%20IFU.pdf. Access 18 May, 2016.
Laryngoscopes
Anonymous. McGrath MAC video laryngoscope operator's manual. Available at: https://www.physio-control.com/uploadedFiles/Physio85/Contents/Emergency_Medical_Care/Products/PreHospital/MAC%20EMS%20IFU.pdf. Access 18 May, 2016.
Anonymous. GlideScope. Available at: http://www.verathon.com/assets/0900-4200-02-60.pdf. Accessed 18 May, 2016.
Emerging Pathogens, Antibiotic-Resistant Bacteria, and Bioterrorism Agents
Food and Drug Administration. FDA-cleared sterilants and high level disinfectants with general claims for processing reusable medical and dental devices, March 2015. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm. Accessed 19 May, 2016.
Summary
References
Centers for Disease Control and Prevention. National hospital discharge survey: 2010 table, procedures by selected patient characteristics-number by procedure category and age. 2010.
- Burden of gastrointestinal disease in the United States: 2012 update.Gastroenterology. 2012; 143: 1179-1187
- New Delhi metallo-beta-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes.JAMA. 2014; 312: 1447-1455
- Endoscopic retrograde cholangiopancreatography-associated AmpC Escherichia coli outbreak.Infect Control Hosp Epidemiol. 2015; 36: 634-642
- Endoscope reprocessing methods: a prospective study on the impact of human factors and automation.Gastroenterol Nurs. 2010; 33: 304-311
- Transmission of infection by flexible gastrointestinal endoscopy and bronchoscopy.Clin Microbiol Rev. 2013; 26: 231-254
- How to assess risk of disease transmission to patients when there is a failure to follow recommended disinfection and sterilization guidelines.Infect Control Hosp Epidemiol. 2007; 28: 146-155
- Lessons learned from outbreaks and pseudo-outbreaks associated with bronchoscopy.Infect Control Hosp Epidemiol. 2012; 33: 230-234
Centers for Disease Control and Prevention. Immediate need for healthcare facilities to review procedures for cleaning, disinfecting, and sterilizing reusable medical devices. 2015. Available at: http://emergency.cdc.gov/han/han00382.asp. Accessed 18 May, 2016.
- Disinfection, sterilization and control of hospital waste.in: Bennett J.E. Dolan R. Blaser M.J. Principles and practice of infectious diseases. Elsevier Saunders, Philadelphia2015: 3294-3309
- Disinfection, Sterilization and Antisepsis: An Overview.Am J Infect Control. 2016; 44: e1-e66
- Cleaning, disinfection and sterilization.in: Grota P. APIC text of infection control and epidemiology. 4th edition. Association for Professionals in Infection Control and Epidemiology, Inc., Washington, DC2014: 31.1-31.15
- Guideline for disinfection and sterilization in healthcare facilities, 2008.Centers for Disease Control and Prevention, Atlanta (GA)2008 (Available at:)
Rutala WA, Weber DJ. Disinfection and sterilization in healthcare facilities. In: Han J, editor Practical healthcare epidemiology. 4th edition: University of Chicago Press, in press.
- Chemical disinfection of medical and surgical materials.in: Lawrence C. Block S.S. Disinfection, sterilization, and preservation. Lea & Febiger, Philadelphia1968: 517-531
- Guidelines for environmental infection control in health-care facilities.MMWR Morb Mortal Wkly Rep. 2003; 52: 1-44
- Disinfection and sterilization of prion-contaminated medical instruments, reply to Belay.Infect Control Hosp Epidemiol. 2010; 31: 1306-1307
- Efficacy of a washer-disinfector in eliminating healthcare-associated pathogens from surgical instruments.Infect Control Hosp Epidemiol. 2014; 35: 883-885
Food and Drug Administration. FDA-cleared sterilants and high level disinfectants with general claims for processing reusable medical and dental devices, March 2015. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm. Accessed 19 May, 2016.
Rutala WA, Weber DJ. Disinfection and sterilization in healthcare facilities. In: Han J, ed. SHEA practical healthcare epidemiology University of Chicago Press.
- Guidelines for infection control in dental health-care settings–2003.MMWR Recomm Rep. 2003; 52: 1-61
- Disinfection: is it time to reconsider Spaulding?.J Hosp Infect. 2011; 78: 163-170
Food and Drug Administration. Brief summary of the gastroenterology and urology devices panel meeting. 2015.
- Gastrointestinal endoscopes: a need to shift from disinfection to sterilization?.JAMA. 2014; 312: 1405-1406
- ERCP scopes: what can we do to prevent infections?.Infect Control Hosp Epidemiol. 2015; 36: 643-648
- Outbreak of Pseudomonas aeruginosa surgical site infections after arthroscopic procedures: Texas, 2009.Infect Control Hosp Epidemiol. 2011; 32: 1179-1186
- Microbial contamination on used surgical instruments.Infect Control Hosp Epidemiol. 2014; 35: 1068-1070
- Disinfection of a probe used in ultrasound-guided prostate biopsy.Infect Control Hosp Epidemiol. 2007; 28: 916-919
- Effective high-level disinfection of cystoscopes: is perfusion of channels required?.Infect Control Hosp Epidemiol. 2016; 37: 228-231
- Disinfection of an infrared coagulation device used to treat hemorrhoids.Am J Infect Control. 2012; 40: 78-79
- Role of environmental contamination in the transmission of vancomycin-resistant enterococci.Infect Control Hosp Epidemiol. 1997; 18: 306-309
- Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species.Am J Infect Control. 2010; 38: S25-S33
- Outbreaks associated with contaminated antiseptics and disinfectants.Antimicrob Agents Chemother. 2007; 51: 4217-4224
- Stability and bactericidal activity of chlorine solutions.Infect Control Hosp Epidemiol. 1998; 19: 323-327
- Multisociety guideline on reprocessing flexible GI endoscopes: 2011.Infect Control Hosp Epidemiol. 2011; 32: 527-537
- Standards of infection control and reprocessing of flexible gastrointestinal endoscopes.Gastroenterol Nurs. 2013; 36: 293-303
- Risk of transmission of carbapenem-resistant Enterobacteriaceae and related “superbugs” during gastrointestinal endoscopy.World J Gastrointest Endosc. 2014; 6: 457-474
- Persistent contamination on colonoscopes and gastroscopes detected by biologic cultures and rapid indicators despite reprocessing performed in accordance with guidelines.Am J Infect Control. 2015; 43: 794-801
- Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009.Euro Surveill. 2010; 15 ([pii:19734])
- Studies on the bioburden on medical devices and the importance of cleaning.in: Rutala W.A. Disinfection, sterilization and antisepsis: principles and practices in healthcare facilities. Association for Provessionals in Infection Control and Epidemiology, Washington, DC2000: 63-69
- Worst-case soiling levels for patient-used flexible endoscopes before and after cleaning.Am J Infect Control. 1999; 27: 392-401
- FDA labeling requirements for disinfection of endoscopes: a counterpoint.Infect Control Hosp Epidemiol. 1995; 16: 231-235
Food and Drug Administration. Brief summary of the gastroeneterology and urology devices panel meeting, May 14-15, 2015. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ucm445590.htm. Accessed 18 May, 2016.
- Is biofilm accumulation on endoscope tubing a contributor to the failure of cleaning and decontamination.J Hosp Infect. 2004; 58: 224
- The role of biofilms in reprocessing medical devices.in: WA R. Disinfection, sterilization and antisepsis: principles, practices, current issues, new research, and new technologies. Association for Professionals in Infection Control and Epidemiology, Washington, DC2010: 223-229
- Effectiveness of current disinfection procedures against biofilm on contaminated GI endoscopes.Gastrointest Endosc. 2016; 83: 944-953
- Correlation between the growth of bacterial biofilm in flexible endoscopes and endoscope reprocessing methods.Am J Infect Control. 2014; 42: 1203-1206
- Delayed reprocessing of endoscopes.Gastrointest Endosc. 2011; 73: 853-854
- Outbreaks of carbapenem-resistant Enteriobacteriaceae infections associated with duodenoscopes: what can we do to prevent infections?.Am J Infect Control. 2016; 44: e47-e51
- The role played by contaminated surfaces in the transmission of nosocomial pathogens.Infect Control Hosp Epidemiol. 2011; 32: 687-699
- Environmental contamination makes an important contribution to hospital infection.J Hosp Infect. 2007; 65: 50-54
- Role of the environment in the transmission of Clostridium difficile in health care facilities.Am J Infect Control. 2013; 41: S105-S110
- Disinfectants used for environmental disinfection and new room decontamination technology.Am J Infect Control. 2013; 41: S36-S41
- Contamination of hands with methicillin-resistant Staphylococcus aureus after contact with environmental surfaces and after contact with the skin of colonized patients.Infect Control Hosp Epidemiol. 2011; 32: 185-187
- Methods for assessing the adequacy of practice and improving room disinfection.Am J Infect Control. 2013; 41: S20-S25
- Risk of acquiring antibiotic-resistant bacteria from prior room occupants.Arch Intern Med. 2006; 166: 1945-1951
- Evaluation of hospital room assignment and acquisition of Clostridium difficile infection.Infect Control Hosp Epidemiol. 2011; 32: 201-206
- Does improving surface cleaning and disinfection reduce health care-associated infections?.Am J Infect Control. 2013; 41: S12-S19
- Evaluating hygienic cleaning in health care settings: what you do not know can harm your patients.Am J Infect Control. 2010; 38: S41-S50
- Monitoring the effectiveness of hospital cleaning practices by use of an adenosine triphosphate bioluminescence assay.Infect Control Hosp Epidemiol. 2009; 30: 678-684
- Interventional evaluation of environmental contamination by vancomycin-resistant enterococci: failure of personnel, product or procedure?.J Hosp Infect. 2009; 71: 123-131
- Impact of an environmental cleaning intervention on the presence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci on surfaces in intensive care unit rooms.Infect Control Hosp Epidemiol. 2008; 29: 593-599
- Reduction of Clostridium difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods.BMC Infect Dis. 2007; 7: 61
Leas BF, SN, Han JH, et al. Environmental cleaning for the prevention of healthcare-associated infection. Technical brief No. 22 (prepared by the ECRI Institute – Penn Agency for Healthcare Research and Quality. Available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1951. Accessed 18 May, 2016.
- A quantitative approach to defining “high-touch” surfaces in hospitals.Infect Control Hosp Epidemiol. 2010; 31: 850-853
- Microbial assessment of high-, medium-, and low-touch hospital room surfaces.Infect Control Hosp Epidemiol. 2013; 34: 211-212
- Applications of ultraviolet germicidal irradiation disinfection in health care facilities: effective adjunct, but not stand-alone technology.Am J Infect Control. 2010; 38: S13-S24
- Evaluation of a pulsed xenon ultraviolet disinfection system for reduction of healthcare-associated pathogens in hospital rooms.Infect Control Hosp Epidemiol. 2015; 36: 192-197
- Room decontamination with UV radiation.Infect Control Hosp Epidemiol. 2010; 31: 1025-1029
- Room decontamination using an ultraviolet-C device with short ultraviolet exposure time.Infect Control Hosp Epidemiol. 2014; 35: 1070-1072
- Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms.BMC Infect Dis. 2010; 10: 197
- Terminal decontamination of patient rooms using an automated mobile UV light unit.Infect Control Hosp Epidemiol. 2011; 32: 737-742
- Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting.Infect Control Hosp Epidemiol. 2008; 29: 723-729
- Tackling contamination of the hospital environment by methicillin-resistant Staphylococcus aureus (MRSA): a comparison between conventional terminal cleaning and hydrogen peroxide vapour decontamination.J Hosp Infect. 2004; 57: 31-37
- Environmental methicillin-resistant Staphylococcus aureus (MRSA) disinfection using dry-mist-generated hydrogen peroxide.J Hosp Infect. 2008; 70: 35-41
- Use of hydrogen peroxide vapor for deactivation of Mycobacterium tuberculosis in a biological safety cabinet and a room.J Clin Microbiol. 2007; 45: 810-815
- Rapid recontamination with MRSA of the environment of an intensive care unit after decontamination with hydrogen peroxide vapour.J Hosp Infect. 2007; 66: 360-368
- Evaluation of hydrogen peroxide vapour as a method for the decontamination of surfaces contaminated with Clostridium botulinum spores.J Microbiol Methods. 2005; 60: 403-411
- Efficacy of vaporized hydrogen peroxide against exotic animal viruses.Appl Environ Microbiol. 1997; 63: 3916-3918
- Vapor-phase hydrogen peroxide as a surface decontaminant and sterilant.Appl Environ Microbiol. 1990; 56: 503-506
- Use of hydrogen peroxide vapour for environmental control during a Serratia outbreak in a neonatal intensive care unit.J Hosp Infect. 2005; 61: 364-366
- Activity of a dry mist hydrogen peroxide system against environmental Clostridium difficile contamination in elderly care wards.J Hosp Infect. 2008; 70: 136-141
- Airborne hydrogen peroxide for disinfection of the hospital environment and infection control: a systematic review.J Hosp Infect. 2011; 78: 171-177
Weber DJ, Rutala W, Anderson DJ, et al. Effectiveness of UV devices and hydrogen peroxide systems for terminal room decontamination: focus on clinical trials. Am J Infect Control, 2016.;44(5 Suppl):e77-e84.
- Selection of the ideal disinfectant.Infect Control Hosp Epidemiol. 2014; 35: 855-865
- Assessing the risk of disease transmission to patients when there is a failure to follow recommended disinfection and sterilization guidelines.Am J Infect Control. 2013; 41: S67-S71
- Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants.J Antimicrob Chemother. 2014; 69: 1546-1550
- Susceptibility of HPV 16 and 18 to high-level disinfectants indicated for semi-critical ultrasound probes.J Med Virol. 2015; 88: 1076-1080
- Effectiveness of a hydrogen peroxide mist (Trophon®) system in inactivating healthcare pathogens on surface and endocavitary probes.Infect Control Hosp Epidemiol. 2016; 37: 613-614
- Evaluation of an automated high-level disinfection technology for ultrasound transducers.J Infect Public Health. 2014; 7: 153-160
- Disinfection and sterilization in physician practices and specialty clinics.Am J Infect Control. 2016; 44: e63-e67
- Reprocessing semicritical items: current issues and new technologies.Am J Infect Control. 2016; 44: e53-e62
Anonymous. McGrath MAC video laryngoscope operator's manual. Available at: https://www.physio-control.com/uploadedFiles/Physio85/Contents/Emergency_Medical_Care/Products/PreHospital/MAC%20EMS%20IFU.pdf. Access 18 May, 2016.
- Outbreak of cystoscopy related infections with Pseudomonas aeurginosa: New Mexico, 2007.J Urol. 2008; 180: 588-592
- Recommendations to resolve inconsistent guidelines for the reprocessing of sheathed and unsheathed rigid laryngoscopes.Infect Control Hosp Epidemiol. 2007; 28: 504-507
- Prevention of disease transmission during flexible laryngoscopy.Am J Infect Control. 2007; 35: 536-544
- Reassessment of the risk of healthcare-acquired infection during rigid laryngoscopy.J Hosp Infect. 2008; 68: 101-107
- Nosocomial contamination of laryngoscope handles: challenging current guidelines.Anesth Analg. 2009; 109: 479-483
- Contamination of laryngoscope handles.J Hosp Infect. 2010; 74: 123-128
- Incidence of visible and occult blood on laryngoscope blades and handles.AANA J. 1997; 65: 241-246
Anonymous. GlideScope. Available at: http://www.verathon.com/assets/0900-4200-02-60.pdf. Accessed 18 May, 2016.
- Evaluating environmental persistence and disinfection of the Ebola virus Makona variant.Viruses. 2015; 7: 1975-1986
- The inactivation of viruses by germicides.Chem Specialists Manuf Assoc Proc. 1963; 49: 116-118
- Sporicidal activity of a new low-temperature sterilization technology: the Sterrad 50 sterilizer.Infect Control Hosp Epidemiol. 1999; 20: 514-516
- Susceptibility of antibiotic-susceptible and antibiotic-resistant hospital bacteria to disinfectants.Infect Control Hosp Epidemiol. 1997; 18: 417-421
- Susceptibility of vancomycin-resistant enterococci to environmental disinfectants.Infect Control Hosp Epidemiol. 1997; 18: 195-199
- Antimicrobial activity of home disinfectants and natural products against potential human pathogens.Infect Control Hosp Epidemiol. 2000; 21: 33-38
Article info
Footnotes
Potential Conflicts of Interest: Dr W.A. Rutala is a consultant for Clorox and has received honoraria from 3M. Dr D.J. Weber is a consultant for Clorox and Germitec.